Mid-period crossings: the quarter's story is things that started during it and are still completing
The model's full reasoning — Q4 2021 call → NOWe need to determine if the earnings call transcript describes a period with real business activity that started partway through the period, and whether management conveys that the reported numbers lag the current run rate because the activity is still ramping. We need to look for concrete starts narrated as starts, and an incomplete climb with printed numbers lagging. Possible candidates: - HRD solution launched. The transcript mentions "we recently announced onboarding a leading Taiwanese genetic testing company called SOFIVA GENOMICS... first clinical institution in this region to offer SOPHiA’s newly launched HRD Solution... validation is already underway." Also AstraZeneca partnership to expand access to in-house HRD testing. This seems like a new product offering that started generating revenue? But the question is about the reported period (Q4 2021). The HRD solution was launched, and customers are adopting it. Is this a start that happened during or around the reported period? The transcript says "newly launched" and mentions "we recently announced onboarding" - that might be around Q4. However, does management say that the reported numbers only partially capture this and that the climb is incomplete? They discuss momentum, but not explicitly that Q4 numbers lag because HRD started partway and is ramping. - CarePath: introduced at J.P. Morgan in January 2022, so after Q4. Also DEEP-Lung-IV study launched at RSNA in November, that's within Q4. That's a study, not a revenue-generating activity. They say "Since launching the study in November, 16 sites across six countries have signed up... already enrolled hundreds of patients... will provide preliminary findings at ASCO." That's a study, not a commercial product generating revenue. Not a business activity that produces revenue. - Partnerships: GE collaboration, Ambry Genetics - letter of intent, not yet started generating revenue. - Biopharma: Peter Casasanto talks about opportunities but no clear revenue starts. - Net dollar retention, customer counts, etc. are routine.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AIN | Albany International Corp. | Q3 2023 | 2023-11-07 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
AFL · Q2 2023 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the Japan Post cancer insurance launch in early April, which began selling the product and drove a 60% sales increase as a major contributor. They describe the activity as real and transacting, with Dan Amos noting the significant contribution from the new product. Yoshizumi confirms gradual increase going forward, and Fred highlights runway for more agents and sales calming down after initial jump, indicating the Q2 numbers reflect partial ramp-up rather than full run-rate.
ESE · Q2 2016 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the real mid-period start of Plastique's contribution (acquired partway through Q2, with two months of performance noted and "early performance consistent with our acquisition forecast"), treated as a key new segment. It also explicitly addresses the incomplete climb, noting that the reported Q 2 numbers lag due to partial contribution and that Q3/Q4 will see fuller periods plus seasonality, with the business already running at a higher level as the ramp continues.
PSX · Q4 2016 → YESThe question is about whether management's account of the just-reported period is built substantially around real business activity that crossed from not-happening to happening partway through the per...YES The transcript shows management centering the Q4 story on the Freeport LPG Export Terminal's real start: commissioning completed smoothly, first commercial cargo shipped mid-December (partial Q4 contribution), with full-quarter costs incurred but only partial revenue, and explicit ramp to near-capacity loading in January onward.